EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Proteomic analysis reveals divergent inflammatory mechanisms of COVID-associated Guillain-Barré syndrome

Can Ulutekin, Amelie Can, Lenka Súkeníková, Luis Querol, Raul Juntas-Morales, Arnau Llauradó, Anelia Dietmann, Tobias Weiss, Daniela Latorre, Burkhard Becher, Florian Ingelfinger, Bettina Schreiner

Journal of Molecular Medicine · 2026-12 · 104 (1)

DOI: 10.1007/s00109-026-02698-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Medicine, online erschienen am 04.07.2026. Verfasst von Can Ulutekin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Guillain-Barre Syndrome, COVID-19, Proteomics. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Zurich.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Guillain-Barré syndrome (GBS) is an acute immune-mediated neuropathy triggered by infections, with poorly understood pathophysiological diversity. COVID-19-associated GBS (COVID-GBS) is a rare but severe post-infectious condition, and its immune mechanisms remain unclear. We profiled immune mediators in cerebrospinal fluid (CSF) and serum from COVID-GBS patients, comparing them to non-COVID GBS (Control-GBS), COVID-19 patients without neurological complications (COVID-no-GBS) and non-inflammatory neuropathy controls (Neuropathy-no-GBS). To gain mechanistic insights, we integrated publicly available single-nucleus transcriptomic data from sural nerve biopsies of neuropathy patients. IL-8 was confirmed as a key cytokine in GBS. Analysis of publicly available single-nucleus transcriptomic data from non-GBS sural nerve biopsies suggested myeloid cells as potential sources of IL-8, with evidence of autocrine signaling capacity. LIF and CD8A emerged as novel biomarkers, with this transcriptomic analysis indicating that LIF receptor components are expressed on endothelial and stromal cells, suggesting these as potential cellular targets. COVID-GBS patients exhibited unique CSF alterations and distinct serum profiles marked by altered NK cell activity, cytotoxic T-cell responses, and myeloid differentiation. Moreover, associations between inflammatory, extracellular matrix, and regulatory markers with clinical disability differed between COVID-GBS and Control-GBS, pointing to divergent immune mechanisms. Our findings suggest that GBS involves myeloid-driven cytokine responses and local LIF signaling. Analysis of publicly available transcriptomic data from non-GBS sural nerve biopsies suggests potential cellular sources and targets, though validation in GBS-affected tissue is needed. COVID-GBS features a distinct immune signature involving localized and systemic inflammation. These insights deepen our understanding of GBS pathogenesis and nominate candidate biomarkers for further validation and potential therapeutic targeting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Guillain-Barre SyndromeCOVID-19ProteomicsHumansFemaleSARS-CoV-2BiomarkersMaleMiddle AgedInterleukin-8InflammationSural NerveAdultAgedTranscriptome

Stichwörter der Autor:innen

COVID-19Guillain-Barré syndrome (GBS)Inflammation-related protein biomarkersSARS-CoV-2

Substanzen

BiomarkersInterleukin-8

Autor:innen und Institutionen

  • Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • Institute of Microbiology, ETH Zurich, Zurich, Switzerland.
  • Neuromuscular Diseases Unit, Hospital de la Santa Creu i Sant Pau, IR SANT Pau, Barcelona, Spain.
  • Neuromuscular Diseases Unit, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron, Barcelona, Spain.
  • Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.

Förderung

  • University of Zurich

Zitieren

APA

Ulutekin, C., Can, A., Súkeníková, L., Querol, L., Juntas-Morales, R., Llauradó, A., Dietmann, A., Weiss, T., Latorre, D., Becher, B., Ingelfinger, F., & Schreiner, B. (2026). Proteomic analysis reveals divergent inflammatory mechanisms of COVID-associated Guillain-Barré syndrome. Journal of Molecular Medicine, 104(1). https://doi.org/10.1007/s00109-026-02698-2

Vancouver

Ulutekin C, Can A, Súkeníková L, Querol L, Juntas-Morales R, Llauradó A, et al. Proteomic analysis reveals divergent inflammatory mechanisms of COVID-associated Guillain-Barré syndrome. Journal of Molecular Medicine. 2026;104(1). doi:10.1007/s00109-026-02698-2

BibTeX
@article{Ulutekin2026,
  author = {Ulutekin, Can and Can, Amelie and Súkeníková, Lenka and Querol, Luis and Juntas-Morales, Raul and Llauradó, Arnau and Dietmann, Anelia and Weiss, Tobias and Latorre, Daniela and Becher, Burkhard and Ingelfinger, Florian and Schreiner, Bettina},
  title = {Proteomic analysis reveals divergent inflammatory mechanisms of COVID-associated Guillain-Barré syndrome},
  journal = {Journal of Molecular Medicine},
  year = {2026},
  volume = {104},
  number = {1},
  doi = {10.1007/s00109-026-02698-2}
}
Kostenlos starten →